Product
Regorafenib and Irinotecan
1 clinical trial
2 indications
Indication
Stomach AdenocarcinomaIndication
Gastroesophageal Junction AdenocarcinomaClinical trial
A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal AdenocarcinomasStatus: Terminated, Estimated PCD: 2022-05-19